Clinical Trial Update: Bioequivalence Trial of 2 Dose Strengths of BI 201335 NA Soft Gelatine Capsules [Phase 1]

View source ↗

Summary

A Phase 1 bioequivalence trial comparing two dose strengths of BI 201335 NA soft gelatin capsules has completed, with results posted in July 2015. The study tar…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• BI 201335 NA soft gelatin capsules (BI 201335)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Hepatitis C | Phase 1 | Status: COMPLETED | Results posted: 2015-07-31